Abebe Akalu

Title: Abebe Akalu: Innovator in Angiogenesis Inhibition

Introduction

Abebe Akalu is a prominent inventor based in Forest Hills, NY (US). He has made significant contributions to the field of medical research, particularly in the area of angiogenesis inhibition. With a total of 3 patents to his name, Akalu's work focuses on innovative methods for treating tumors and related conditions.

Latest Patents

Among his latest patents are CLK-peptide and SLK-peptide. These inventions describe methods for inhibiting angiogenesis in tissues by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV. This antagonist exhibits substantially greater affinity for the denatured form than for the native triple helical form of collagen type-IV. The methods outlined in these patents are aimed at therapeutic treatments for tumor growth, tumor metastasis, and restenosis. Additionally, they describe the use of these antagonists as diagnostic markers of angiogenesis in both normal and diseased tissues, applicable in vivo and ex vivo. Furthermore, the inventions detail methods for treating tumors using these antagonists in combination with radiation therapy.

Career Highlights

Abebe Akalu is affiliated with New York University, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on cancer treatment and diagnostics.

Collaborations

Some of his notable coworkers include Peter C Brooks and Jennifer Roth, who have collaborated with him on various research projects.

Conclusion

Abebe Akalu's contributions to the field of angiogenesis inhibition through his innovative patents highlight his role as a key figure in medical research. His work promises to enhance therapeutic strategies for cancer treatment and improve diagnostic methods.